

























	Regimen	OS (months)	Toxicity	Hospitalization Incidence*	Drug Cost (monthly) [§]	Median (Mean) duration (days)*	Total Cos of Care*
/	FOLFIRINOX	11.1	FN – 5% Vomiting – 15% Diarrhea – 13% Neuropathy – 9%	34%	\$300	85 (112)	\$87,971
•	Gemcitabine + nab-paclitaxel	8.5	FN – 3% Diarrhea – 6% Vomiting – NR Neuropathy – 17%	37%	\$8,139	80 (101)	\$80,132
•	Gemcitabine + Erlotinib	6.2	Diarrhea – 6% Infections – 17%	No data	\$7,629	No data	No data
	Gemcitabine + Capecitabine	7.1	Vomiting – 6% Diarrhea – 5% Hand Foot Syndrome – 4%	No data	\$837	No data	No data
	Gemcitabine	6.8	FN – 1% Vomiting – 8% Diarrhea – 2% Neuropathy – 0%	37%	\$157	40 (62)	\$35,083
	Capecitabine	6.0	Vomiting – 5% Diarrhea – 16% Hand Foot Syndrome – 17%	No data	\$794	No data	No data
	5-FU	4.4	Vomiting – 5% Diarrhea – 5%	No data	\$24	No data	No data
=	UHC Pathway regime	en			*UF § CN	IC data /IS Average Sales Price (/	April 2019) or

Regimen	OS (months)	PFS (months)	Toxicity	Drug Cost (monthly)§
Erlotinib	22.8 - 31.8	10.2-13.1	Nausea/Vomiting: 0% Diarrhea: 5% Interstitial lung disease: 2%	\$4,640
Gefitinib	26.8 - 31.8	9.2 - 10.2	Nausea/Vomiting: <1% Diarrhea: 4% Interstitial lung disease: 3%	\$7,800
Dacomitinib	34.1	14.7	Nausea/Vomiting: 1% Diarrhea: 9% Interstitial lung disease: 1%	\$12,400
Afatinib	23.1 - 31.6	11.0	Nausea/Vomiting: 1% Diarrhea: 5- 14% Interstitial lung disease: 1%	\$8,800
Osimertinib	38.6	18.9	Nausea/Vomiting: 1% Diarrhea: 2% Interstitial lung disease: 4% OT prolong: 2%	\$14,900
Erlotinib + Ramucirumab	'not reached'	19.4	Nausea/Vomiting: 1% Diarrhea: 7% Hypertension: 24% Pneumonia: 3% Interstitial lung disease: <1%	\$26,050
IC Pathway regimen			§ CMS Average Sales F	rice (April 2019) or

13

Regimen	os	DFS/iDFS	Toxicity	Hospitalization Incidence*	Total Drug Cost [§]	Median (Mean) duration (da <u>ys)</u> *	Total Cost of Care*
АС → ТН	3yr: 94% ^A 3yr: 96%	3yr DFS: 87% ^A 3yr iDFS: 93%	FN: 11% Diarrhea: 3% Neuropathy: 1% CHF: <1%	11%	\$87,070	274 (280)	\$180,164
AC → TH-P	No Data ^A 3yr: 97%	No Data ^A 3yr iDFS: 94%	FN: 13% Diarrhea: 8% Neuropathy: NR CHF: <1%	25%	\$184,398	300 (284)	\$279,114
Paclitaxel wkly +Trastuzumab	NR	3yr iDFS: 99% (Stage 1)	FN: NR Diarrhea: 2% Neuropathy: 3% CHF: <1%	8%	\$85,318	223 (216)	\$134,108
тсн	5yr: 91% ^A 3yr: 96%	5yr DFS: 81% ^A 3yr iDFS: 93%	FN: 10-12% Diarrhea: 5-6% CHF: <1% Decrease LVEF: 9%	13%	\$114,268	252 (229)	\$166,371
TCH-P	No Data ^A 3yr: 97%	No Data ^A 3yr iDFS: 94%	FN: 10% Diarrhea: 18% CHF: <1%	24%	\$211,656	231 (228)	\$232,803
AC → docetaxel + trastuzumab	5yr: 92%	5yr DFS: 84%	FN: 11% Diarrhea: 6% CHF: 2% Decrease LVEF: 19%	33%	\$87,650	378 (335)	\$221,046
= UHC Pathway regir	men			[^] Data not specif *UHC data	ic to chemothera §CMS Ave	py regimen reported in a erage Sales Price (April	APHINITY trial 2019) or WAC

		<i>, , , , , , , , , , , , , , , , , , , </i>	u cost
	Chemotherapy + Trastuzumab + Pertuzumab	Chemotherapy + Trastuzumab	Evaluation
Efficacy	3yr OS: 97% 6yr OS: 95% 3yr invasive DFS: 94% 6yr invasive DFS: 91% LN + iDFS: 88%	3yr OS: 96% 6yr OS: 94% 3yr invasive DFS: 93% 6yr invasive DFS: 88% LN+ iDFS: 83%	No difference in OS (p=0.17) 1% absolute benefit in IDFS at 3 years and 3% (4.5% in LN+) at 6 years that did not translate to OS increase not clinically meaningful.
Foxicity Grade 3/4	Febrile neutropenia: 10 - 13% Diarrhea: 8 - 18% NYHA class III/IV CHF: 0.4 - 0.7% Cardiac events: 0.4% - 0.8%	Febrile neutropenia: 10% - 12% Diarrhea: 3 - 6% NYHA class III/IV CHF: 0.2 - 0.3% Cardiac events: 0.2 - 0.4%	Increase in toxicity with pertuzumab primarily related to diarrhea.
lospitalization	24%	12%	Although studies report minimal toxicity difference, 12% increase in hospitalizations associated with pertuzumab containing regimens in RVVE.
Drug Cost§	\$184,400 - \$211,600	\$85,300 - \$114,200	>\$100,000
Fotal Cost*	\$232,800- \$279,100	\$134,100 - \$180,100	>\$100,000
Drug Cost [§] Total Cost* hemotherapy = FE ocetaxel/carboplatitio pource: Von Minckw. OPTUMHealth	\$184,400 - \$211,600 \$232,800- \$279,100 C/FAC→ docetaxel or paclitaxel, AC/EC n <i>iz NEJM 2017</i>	\$85,300 - \$114,200 \$134,100 - \$180,100 → docetaxel or paclitaxel; or	RWE. >\$100,000 >\$100,000 *UHC data \$CMS Average Sales Price (April 2019)





















